Systems and methods for sealing tissue sites may comprise coring tissue at a target site such that a tissue core is removed from the target site thereby creating a core cavity at the target site and causing sealing of at least a portion of the target site

A retinal phototherapy or photostimulation system includes a laser console generating at least one treatment beam having parameters to photostimulate or treat, while not permanently damaging, a retinal target tissue. The parameters of the at least one treatment beam are fixed so as not to be alterable by a medical provider. A projector or camera projects the at least one treatment beam onto at least a portion of the retina, and a scanning mechanism controllably directs the at least one treatment beam to treatment areas of the retina.

There is presented a removable high-intensity focused ultrasound (HIFU) transducer and supporting system that allows for HIFU transducer assemblies and other therapeutic ultrasound assemblies to be attached to third party positioning, imaging, or guidance systems while maintaining the required focal-zone positioning ability and the required acoustic energy coupling to tissue, to mechanically or automatically ablate a target volume in unimpeded fashion. There is provided an acoustically transparent and pliable vessel that has an open top end and filled with acoustic coupling fluid, capable of holding the transducer assembly and distal end of the positioning system within it as it executes the HIFU treatment plan/process. The vessel is held in place using a transducer/positioning system and independent external fixturing mechanism.

Provided are a high-intensity focused ultrasound apparatus (10) and a control method. According to the high-intensity focused ultrasound apparatus (10), by providing a focusing transducer (120) having a freely transformable shape, after an entire transducer assembly (100) extends into an inner cavity of an object to be treated, the transducer assembly (100) can extend through a narrow part into the inner cavity of an object to be treated, and after extending into the inner cavity of the object to be treated, the shape of the focusing transducer (120) in the transducer assembly (100) changes, so that the effective area of the focusing transducer (120) increases, and the ultrasonic energy produced increases, thereby enhancing the irradiation intensity for a region to be treated, and satisfying normal operation requirements of the transducer assembly (100).

Apparatus and methods for treating conditions such as rhinitis are disclosed herein where a distal end of a probe shaft is introduced through the nasal cavity where the distal end has an end effector with a first configuration having a low-profile which is shaped to manipulate tissue within the nasal cavity. The distal end may be positioned into proximity of a tissue region having a post nasal nerve associated with a middle or inferior nasal turbinate. Once suitably positioned, the distal end may be reconfigured from the first configuration to a second configuration which is shaped to contact and follow the tissue region and the post nasal nerve may then be ablated via the distal end. Ablation may be performed using various mechanisms, such as cryotherapy, and optionally under direct visualization.

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

A system and method for prostate cancer treatment under local anesthesia includes creating a superficial skin and subcutaneous block in a perineal area of a patient by administering a first anesthetizing agent; creating a deep nerve block under ultrasound guidance by administering a second anesthetizing agent, the second anesthetizing agent infiltrating cavernosal nerve bundle tissue and periprostatic space; and ablating prostate tissue. The office-based method, statistical models and computer generated treatment plans identify and ablate prostate tissue containing cancer through or via the perineum while preserving prostate function, and critical anatomical structures. Multiple technologies are integrated and processed to deliver a safe treatment procedure, under local anesthesia by integrating the information of magnetic resonance imaging and planning the ablative treatment using algorithms that ensure maximal precision in both killing cancerous tissue and preserving healthy tissue along with its corresponding function.

Described herein are systems and methods for performing a denervation procedure and determining an efficacy thereof. Such a system can include an excitation source, a controller, and a catheter with element(s) for delivering first ablation therapy from a first longitudinal location along a biological lumen and delivering second ablation therapy from a second longitudinal location longitudinally spaced apart from the first longitudinal location. A sensing subsystem of the system senses neural activity from a third longitudinal location along the biological lumen, to determine the efficacy of at least one of the first or second ablation therapies.

Methods and devices for treating nasal airways are provided. Such devices and methods may improve airflow through an internal and/or external nasal valve, and comprise the use of mechanical re-shaping, energy application and other treatments to modify the shape, structure, and/or air flow characteristics of an internal nasal valve, an external nasal valve or other nasal airways.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.